T2 BIOSYSTEMS NEW DL-,001
T2 BIOSYSTEMS NEW DL-,001
Aktie · US89853L3024 · TTOO · A3EU63 (XNCM)
Übersicht Finanzkennzahlen
0,13 EUR
-3,23 % -0,004 EUR
Frankfurt (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 19:43

Aktuelle Kurse von T2 BIOSYSTEMS NEW DL-,001

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
TTOO
USD
06.06.2025 19:43
0,15 USD
0,16 USD
-3,23 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
-0,49 % -6,36 % -7,64 % 3,33 % -72,74 % -96,69 % -100,00 %

Firmenprofil zu T2 BIOSYSTEMS NEW DL-,001 Aktie

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Unternehmensdaten

Name T2 BIOSYSTEMS NEW DL-,001
Firma T2 Biosystems, Inc.
Symbol TTOO
Website https://www.t2biosystems.com
Heimatbörse XNCM Frankfurt
WKN A3EU63
ISIN US89853L3024
Wertpapierart Aktie
Sektor Healthcare
Branche Medical - Diagnostics & Research
CEO Mr. Craig R. Jalbert CIRA
Land Vereinigte Staaten von Amerika
Währung EUR
Mitarbeiter 0,1 T
Adresse 101 Hartwell Avenue, 02421 Lexington
IPO Datum 2014-08-07

Ticker Symbole

Name Symbol
Frankfurt 3T2.F
NASDAQ TTOO

Weitere Aktien

Investoren die T2 BIOSYSTEMS NEW DL-,001 die halten, haben auch folgende Aktien im Depot:
American Century ETF Trust Avantis Responsible U.S. Equity ETF
American Century ETF Trust Avantis Responsible U.S. Equity ETF ETF
DEKA FESTZINS ANL 17/33
DEKA FESTZINS ANL 17/33 Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025